Krishnan Suma sold $147K of KRYS
Krishnan Suma (President, R&D) sold 480 shares of Krystal Biotech, Inc. (KRYS) at $305.86 ($0.15M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider behavior but does not introduce new fundamentals (no trial, approval, guidance, or deal).
Market read
Primarily a sentiment/positioning input; likely low impact absent additional fundamental catalysts.
What to watch
The filing does not indicate motivation or future trading; the sale size (480 shares) may be routine relative to holdings (1.4M shares after).
Background
This is an SEC Form 4 insider transaction: an officer/director/10% owner sold KRYS shares under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Krystal Biotech disclosed an open-market sale by President, R&D Krishnan Suma under a pre-arranged 10b5-1 plan, totaling ~$146.8K.
Low likelihood of a sustained price move solely from this Form 4; any impact is likely short-lived sentiment noise.
The filing is an ownership-change disclosure (not an earnings/drug/contract event) and explicitly references a pre-arranged 10b5-1 plan, which reduces interpretive weight.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated or sizable insider sales can coincide with internal risk perceptions; traders may watch for follow-on selling or other insider actions.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the insider transaction disclosure (Form 4) involving an open-market sale by an R&D president under 10b5-1.
- insiderKrishnan Suma
President, R&D; officer/director/10% owner who sold 480 shares on 2026-06-04.
